Rich Stuart

CMO Rich Stuart buys 5,000 TENX shares in 2 transactions for $50,792.50 ($10.10–$10.22), raising stake to 5,266 shares.

Rich Stuart, Chief Medical Officer of Tenax Therapeutics, executed 2 separate purchases totaling 5,000 shares for $50,792.50 over consecutive trading days (2025-12-08 and 2025-12-09), bringing his holdings from 266 shares to 5,266 shares—a +1879.7% increase in position size. The purchases occurred at $10.10 and $10.22, near the upper end of the 52-week range ($5.10–$10.30), while the current price of $9.82 is -4.7% below the 52-week high. The company reported zero revenue in its latest quarter and negative net income of $-15,804,000.00, indicating a pre-revenue stage business burning cash. These large purchases by a C-suite executive in a financially distressed biotech follow three prior buy transactions at this ticker within the preceding week, establishing a pattern of accumulation despite the company's lack of profitability and revenue generation.

CMO Rich Stuart purchases 5,000 shares across 3 days (Dec 2-4) at blended avg $9.12; stock at 52-week high of $9.65.

Rich Stuart (Chief Medical Officer) executed 3 separate purchases totaling 5,000 shares for $45,621.80 between December 2–4, 2025, at prices ranging from $9.01 to $9.20 per share. The buys occur as the stock trades at its 52-week high of $9.65, with the broader context showing a 30-day price increase of +36.1% and a 90-day increase of +61.0%. However, the company's fundamental position remains precarious: revenues in the latest quarter are $0.00, net income is negative at $-15,804,000.00, and the market capitalization stands at $60,250,498.75. This executive accumulation of shares occurs in the context of an unprofitable biopharmaceutical company that has experienced recent price momentum but lacks current revenue generation.